Can we buy Glenmark Life Sciences IPO?

Can we buy Glenmark Life Sciences IPO?

Glenmark Life Sciences is launching its IPO. The public offer comprises a fresh issue of equity shares worth Rs. 1,160 crores and offer for sale of 63 lakh equity shares by its parent company Glenmark Pharmaceuticals Ltd….Glenmark Life Sciences IPO Closed.

IPO date 27 Jul 2021 – 29 Jul 2021
(D)RHP View

Is Glenmark Pharma and Glenmark life sciences same?

Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals, is a leading developer and manufacturer of select high-value, non-commoditised active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes.

Who is Glenmark Life Sciences IPO registrar?

KFintech Private Limited
The retail portion of the ₹1513 crore IPO was subscribed 14.63 times while qualified institutional buyers 36.97 times and non-institutional investors 122.54 times. KFintech Private Limited is the registrar of Glenmark Life Sciences IPO and will manage the share allocation.

READ ALSO:   How many US presidents were there?

How many people applied for Glenmark IPO?

ThinkStock Photos Glenmark Life Sciences IPO received more than 39 lakh applications, the second-highest ever after Reliance Power IPO in 2008.

What will be Glenmark life sciences listing price?

Glenmark Life Sciences made a quiet debut on the bourses with the shares of the company getting listed at Rs 751.10, a 4 per cent premium against issue price of Rs 720 per share on the BSE.

Where do I apply for Glenmark IPO?

Glenmark Life Sciences Ltd IPO Register

  1. Phone: 04067162222, 04079611000.
  2. Email: [email protected].
  3. Website: https://karisma.kfintech.com/

When was Glenmark IPO launched?

Jul 27, 2021
Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs)….Glenmark Life Sciences IPO Details.

IPO Opening Date Jul 27, 2021
IPO Price ₹695 to ₹720 per equity share
Market Lot 20 Shares
Min Order Quantity 20 Shares
Listing At BSE, NSE

What is Glenmark Life Sciences IPO?

Glenmark Life Sciences made a market debut with its shares getting listed at a 4 percent premium over issue price of Rs 720 per share on the bourses. The issue received bids worth Rs 47,759.33 crore as the 1.5 crore shares offer garnered bids for 66.33 crore shares.

READ ALSO:   How does wide format printing work?

How do I check my Glenmark IPO status?

How to Check Glenmark IPO Allotment status from BSE website:

  1. Here enter the company name”Glenmark Life Sciences” in the dropdown.
  2. Now enter your PAN Number in the box.
  3. Enter the captcha and click on the search button.
  4. the status of the application will be displayed on your screen.

How can I check my Glenmark science IPO allotment status?

Here’s how you can check the status: The IPO share allocation can be checked on the BSE’s website. Select Equity and Issue Name (Glenmark Life Sciences); enter Application Number and PAN Number; click on the Search button to know the application status.

Is Glenmark Life Sciences IPO overpriced?

Glenmark Life Sciences made a market debut with its shares getting listed at a 4 percent premium over issue price of Rs 720 per share on the bourses. Its disappointing listing comes in the backdrop of an IPO frenzy wherein many issues are getting listed on the bourses at steep premium.

What is the status of Glenmark IPO?

Glenmark Life Sciences IPO allotment status is expected on Aug 3, 2021.

What is the Glenmark Life Sciences IPO?

Glenmark Life Sciences is a wholly-owned subsidiary of Glenmark Pharmaceutical and is involved in the rapidly growing active pharmaceutical ingredients (API) sector. The company filed a draft red herring prospectus (DRHP) with the oversight and regulatory body on Friday to start the process for its IPO.

READ ALSO:   Do you need port forwarding to seed?

What is Glenmark Life Sciences’ DRHP?

Glenmark Life Sciences, the API (active pharmaceutical ingredients) vertical of leading drug maker Glenmark Pharmaceuticals has filed a DRHP (draft red herring prospectus) with market regulator, the Securities and Exchange Board of India (SEBI), for its IPO.

What is Glenmark Life Sciences’ red herring prospectus?

Mumbai: Glenmark Life Sciences Ltd on Saturday filed a draft red herring prospectus with the Securities and Exchange Board of India to raise funds through initial public offering. The IPO will consist of a fresh issue of ₹ 1,160 crore and an offer for sale of up to 7.31 million shares by parent Glenmark Pharmaceuticals Ltd.

How did Glenmark Life Sciences perform in Q3 FY 2020-21?

For the third quarter of FY 2020-21, Glenmark’s consolidated sales was at Rs 2,761 crore as against Rs 2,657 crore recording an increase of 3.88 percent. In the same quarter, Glenmark Life Sciences Limited registered consolidated revenue including captive sales of Rs 501 crore as against Rs 409 crore, recording a growth of 22.35 percent.